Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Simms

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Arthritis Care & Research|September 17, 2021
Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal DataLynette Keyes-Elstein, Ashley Pinckney, Ellen Goldmuntz, et al.
Arthritis and Rheumatism|February 28, 2009
MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trialLorinda Chung, Lee Shapiro, David Fiorentino, et al.
Seminars in Arthritis and Rheumatism|April 9, 2014
Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort studyVivien M Hsu, Lorinda Chung, Laura K Hummers, et al.
Arthritis Care & Research|August 29, 2013
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registryLorinda Chung, Robyn T Domsic, Bharathi Lingala, et al.
Arthritis and Rheumatism|April 1, 2009
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trialDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Rheumatology (Oxford, England)|February 2, 2022
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapyAnkoor Shah, Jan Storek, Rob Woolson, et al.
The Journal of Rheumatology|October 3, 2018
Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS RegistryVivien M Hsu, Lorinda Chung, Laura K Hummers, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
The Journal of Rheumatology|February 19, 2013
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trialEmily W Hung, Maureen D Mayes, Roozbeh Sharif, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Arthritis Care & Research|September 17, 2021
Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal DataLynette Keyes-Elstein, Ashley Pinckney, Ellen Goldmuntz, et al.
Arthritis and Rheumatism|February 28, 2009
MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trialLorinda Chung, Lee Shapiro, David Fiorentino, et al.
Seminars in Arthritis and Rheumatism|April 9, 2014
Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort studyVivien M Hsu, Lorinda Chung, Laura K Hummers, et al.
Arthritis Care & Research|August 29, 2013
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registryLorinda Chung, Robyn T Domsic, Bharathi Lingala, et al.
Arthritis and Rheumatism|April 1, 2009
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trialDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Rheumatology (Oxford, England)|February 2, 2022
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapyAnkoor Shah, Jan Storek, Rob Woolson, et al.
The Journal of Rheumatology|October 3, 2018
Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS RegistryVivien M Hsu, Lorinda Chung, Laura K Hummers, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
The Journal of Rheumatology|February 19, 2013
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trialEmily W Hung, Maureen D Mayes, Roozbeh Sharif, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Pageof 3